Literature DB >> 11031221

Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin.

G Helft1, J I Osende, S G Worthley, A G Zaman, O J Rodriguez, E I Lev, M E Farkouh, V Fuster, J J Badimon, J H Chesebro.   

Abstract

There is a need for a rapid antithrombotic effect after the administration of antiplatelet drugs in the setting of acute coronary syndromes and percutaneous interventions. Clopidogrel, a new thienopyridine derivative, is an efficient antiplatelet agent. However, the standard regimen of clopidogrel (75 mg/d) requires 2 to 3 days before significant antithrombotic effects. Patients with stable arterial disease on chronic aspirin therapy (n=20) were treated with clopidogrel either with a front-loaded regimen, 300 mg the first day and 75 mg/d the next 7 days, or with a standard regimen, 75 mg/d for 8 days. Blood thrombogenicity was assessed by quantification of platelet-thrombus formation in an ex vivo perfusion chamber, by ADP-induced platelet aggregation, and by ADP-induced fibrinogen binding. At 2 hours, mean total thrombus area with the standard regimen was not significantly reduced. In contrast, at 2 hours, the mean total thrombus area with the front-loaded regimen was significantly decreased by 23.1+/-8.5% versus baseline (P<0.05). ADP-induced platelet aggregation (with 5 and 10 micromol/L) was also significantly (P<0.05) reduced with the front-loaded regimen at 2 hours, with the mean platelet aggregation being 82.2+/-4.4% and 81.8+/-4.5%, respectively, versus baseline. Similarly, flow cytometry demonstrated a significant decrease (P<0. 05) in the ADP-induced fibrinogen binding (with 0.12 and 0.6 micromol/L) at 2 hours in this front-loaded regimen group (36.1+/-2. 0% and 53.2+/-9.3%). With the standard regimen, platelet activity was not significantly reduced at 2 hours. Our data suggest that a front-loaded regimen of clopidogrel added to aspirin achieves a significant antithrombotic effect at 2 hours in patients with known atherosclerotic disease on chronic aspirin therapy. This provides a rationale for using front-loaded clopidogrel in combination with aspirin in percutaneous coronary interventions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11031221     DOI: 10.1161/01.atv.20.10.2316

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  4 in total

Review 1.  Patient-specific antiplatelet therapy.

Authors:  Ian D Conde; Neal S Kleiman
Journal:  J Thromb Thrombolysis       Date:  2004-02       Impact factor: 2.300

2.  A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study.

Authors:  M Urooj Zafar; Borja Ibáñez; Brian G Choi; David A Vorchheimer; Antonio Piñero; Xiaoping Jin; Raman K Sharma; Juan J Badimon
Journal:  Thromb Haemost       Date:  2009-10-26       Impact factor: 5.249

3.  Development of a perfusion chamber assay to study in real time the kinetics of thrombosis and the antithrombotic characteristics of antiplatelet drugs.

Authors:  Gillian Stephens; Ming He; Connie Wong; Marzena Jurek; Hans-Christian Luedemann; Golnaz Shapurian; Kevin Munnelly; Craig Muir; Pamela B Conley; David R Phillips; Patrick Andre
Journal:  Thromb J       Date:  2012-08-01

4.  Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack.

Authors:  Zixiao Li; Yilong Wang; Xingquan Zhao; Liping Liu; David Wang; Chunxue Wang; Xia Meng; Hao Li; Yuesong Pan; Xianwei Wang; Chunjuan Wang; Xiaomeng Yang; Changqing Zhang; Jing Jing; Ying Xian; S Claiborne Johnston; Yongjun Wang
Journal:  J Am Heart Assoc       Date:  2016-03-21       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.